Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 176

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 176
---
 purchased by the PIPE Investors are registered for resale with the SEC.

- 113 -

CAPITALIZATION The following table sets forth our cash and cash equivalents, short-term investments and capitalization as of September 30, 2024:

| • |     | On an actual basis; and |

| • |     | On an as-adjusted basis to give effect to: (i) the Divestiture,                                                                                                                                                                           
 including the estimated receipt of $100 million as consideration (which assumes no adjustments under the Divestiture Agreement to the base consideration to be paid at the closing), less [●] in estimated transaction fees and expenses; 
 (ii) the payment in full to WuXi Biologics of the total upfront license fee payment of $44 million pursuant to the License Agreement, less [●] in estimated transaction fees and expenses; and (iii) the issuance and sale in the         
 PIPE Financing of 21,592,000 shares of common stock and 20,076,500 Pre-Funded Warrants to acquire common stock for aggregate gross proceeds of $100 million, less [●] in estimated transaction fees and expenses.                         |

You should read the data set forth in the table below in conjunction with (a) our audited consolidated financial statements and the related notes thereto, (b) our unaudited condensed consolidated financial statements and the related notes thereto, and (c) “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in each case included elsewhere in this proxy statement.

|                                                                                                           |     | September 30, 2024               |          |   |     |             |
|:----------------------------------------------------------------------------------------------------------|:----|:---------------------------------|---------:|:--|:----|:------------|
|                                                                                                           |     | Actual                           |          |   |     | As-Adjusted |
|                                                                                                           |     | -in thousands, except share data |          |   |     |             |
|                                                                                                           |     | -unaudited                       |          |   |     |             |
| Cash and cash equivalents and short-term investments                                                      |     | $                                |   62,619 |   |     | $           |
| Stockholders’ equity:                                                                                     |     |                                  |          |   |     |             |
| Common stock, $0.0001 par value, 300,000,000 shares authorized, 24,614,834 shares issued and              
 outstanding, actual; 300,000,000 shares authorized,